Spyre Therapeutics (SYRE)

• Market cap: $6.35B
• 1 day: 0.14%
• 5 days: -1.34%
• 1 month: 42.77%
• 3 months: 115.25%
• 6 months: 224.6%
• Year to date: 139.05%
• 1 year: 475.14%
• 5 years: -59.61%
• 10 years: -66.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Employees: 102